Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial

MLA

John B Buse, et al. “Study Design and Baseline Profile for Adults with Type 2 Diabetes in the Once-Weekly Subcutaneous SEmaglutide Randomized PRAgmatic (SEPRA) Trial.” BMJ Open Diabetes Research & Care, vol. 11, May 2023, p. e003206. EBSCOhost, https://doi.org/10.1136/bmjdrc-2022-003206.

APA

John B Buse, Helene Nordahl Christensen, Brian J Harty, Julie Mitchell, Benjamin P Soule, Emily Zacherle, Mark Cziraky, & Vincent J Willey. (2023). Study design and baseline profile for adults with type 2 diabetes in the once-weekly subcutaneous SEmaglutide randomized PRAgmatic (SEPRA) trial. BMJ Open Diabetes Research & Care, 11, e003206. https://doi.org/10.1136/bmjdrc-2022-003206

Chicago

John B Buse, Helene Nordahl Christensen, Brian J Harty, Julie Mitchell, Benjamin P Soule, Emily Zacherle, Mark Cziraky, and Vincent J Willey. 2023. “Study Design and Baseline Profile for Adults with Type 2 Diabetes in the Once-Weekly Subcutaneous SEmaglutide Randomized PRAgmatic (SEPRA) Trial.” BMJ Open Diabetes Research & Care 11 (May): e003206. doi:10.1136/bmjdrc-2022-003206.